/PRNewswire/ -- Robbins Geller Rudman &amp; Dowd LLP 律师事务所宣布，2023 年 2 月 16 日至 2025 年 2 月 12 日（包括这两个日期）期间购买或收购西方制药服务公司（NYSE: WST）普通股的投资者，有直到 2025 年 7 月 7 日的时间申请成为 West Pharmaceutical 集体诉讼的首席原告。该案标题为 New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.)，指控西方制药及其部分现任和前任高管违反 1934 年证券交易法。
如果您遭受了重大损失并希望担任 West Pharmaceutical 集体诉讼的首席原告，请在此提供您的信息：
https://www.rgrdlaw.com/cases-west-pharmaceutical-services-inc-class-action-lawsuit-wst.html
您也可以通过拨打 800/449-4900 或发送电子邮件至 [email protected] 联系 Robbins Geller 的律师 J.C. Sanchez 或 Jennifer N. Caringal。
案件指控：西方制药设计、制造和销售用于注射药物和医疗产品的封闭和输送系统。
West Pharmaceutical 集体诉讼指控被告在整个诉讼期间做出了虚假和/或误导性的陈述，和/或未能披露：(i) 尽管声称对客户需求有强烈的可见性，并将逆风归因于暂时的 COVID 相关产品去库存，西方制药实际上在其高利润的高价值产品组合中经历了显著且持续的去库存；(ii) 西方制药的 SmartDose 设备，虽然被定位为高利润增长产品，但由于运营效率低下，对西方制药的利润率造成了很大稀释；以及 (iii) 这些利润压力导致了高昂的重组活动风险，包括西方制药退出与长期客户的连续血糖监测（&#34;CGM&#34;）合同。
West Pharmaceutical 集体诉讼进一步指控，2025 年 2 月 13 日，西方制药发布了 2025 年的收入预测，范围在 28.8 亿美元到 29.1 亿美元之间，远低于预期。根据投诉，西方制药将令人失望的指导部分归因于合同制造的逆风，包括失去两家主要 CGM 客户，这些客户已开始转向内部制造下一代设备，因为西方制药&#34;决定不再参与，因为我们的财务门槛无法实现。&#34; West Pharmaceutical 集体诉讼进一步指控，西方制药还透露，其 SmartDose 可穿戴注射器将在 2025 年因降价而变得利润稀释。对此消息，西方制药的股票价格下跌超过 38%。
首席原告流程：1995 年《私人证券诉讼改革法》允许在诉讼期间购买或收购西方制药普通股的任何投资者申请成为 West Pharmaceutical 集体诉讼的首席原告。首席原告通常是寻求救济的潜在集体中财务利益最大的动议者，同时也是潜在集体的典型和适当代表。首席原告代表所有其他集体成员指导 West Pharmaceutical 集体诉讼。首席原告可以选择其选择的律师事务所来进行 West Pharmaceutical 集体诉讼。投资者分享任何潜在未来赔偿的能力并不依赖于担任 West Pharmaceutical 集体诉讼的首席原告。
关于 ROBBINS GELLER：Robbins Geller Rudman &amp; Dowd LLP 是全球领先的律师事务所之一，代表投资者进行证券欺诈和股东诉讼。我们的事务所过去五年中有四年在 ISS 证券集体诉讼服务排名中名列第一，为投资者争取到最多的货币救济。根据 ISS，2024 年我们为证券相关集体诉讼案件追回了超过 25 亿美元的赔偿，超过了接下来五家律师事务所的总和。Robbins Geller 在 10 个办公室拥有 200 名律师，是全球最大的原告律师事务所之一，事务所的律师获得了历史上许多最大的证券集体诉讼赔偿，包括历史上最大的赔偿——72 亿美元——在 In re Enron Corp. Sec. Litig. 案件中。有关更多信息，请访问以下页面：
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
过去的结果并不保证未来的结果。
服务可能由我们任何办公室的律师提供。
联系方式：
Robbins Geller Rudman &amp; Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]
来源 Robbins Geller Rudman &amp; Dowd LLP
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNTEyJk5ld3NJdGVtSWQ9TEE4NDU4OCZUcmFuc21pc3Npb25fSWQ9MjAyNTA1MTIwNTA1UFJfTkVXU19VU1BSX19fX19MQTg0NTg4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNTEyJk5ld3NJdGVtSWQ9TEE4NDU4OCZUcmFuc21pc3Npb25fSWQ9MjAyNTA1MTIwNTA1UFJfTkVXU19VU1BSX19fX19MQTg0NTg4"/>

西氏医药服务

罗宾斯·盖勒·鲁德曼与道德律师事务所（Robbins Geller Rudman & Dowd LLP）宣布，西方制药服务公司（West Pharmaceutical Services, Inc.，纽约证券交易所代码：WST）的投资者，如果在 2023 年 2 月 16 日至 2025 年 2 月 12 日期间遭受了重大损失，可以寻求领导集体诉讼。该诉讼指控违反证券交易法，包括关于产品需求和利润率的误导性陈述。在发布令人失望的收入预测后，西方制药的股票下跌超过 38%。有意的投资者必须在 2025 年 7 月 7 日之前申请，以被考虑为主要原告

, /PRNewswire/ -- The law firm of Robbins Geller Rudman &amp; Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, both dates inclusive (the &#34;Class Period&#34;), have until July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutical class action lawsuit charges West Pharmaceutical as well as certain of West Pharmaceutical's current and former top executives with violations of the Securities Exchange Act of 1934.
<div class="lb-trans">/PRNewswire/ -- Robbins Geller Rudman &amp; Dowd LLP 律师事务所宣布，2023 年 2 月 16 日至 2025 年 2 月 12 日（包括这两个日期）期间购买或收购西方制药服务公司（NYSE: WST）普通股的投资者，有直到 2025 年 7 月 7 日的时间申请成为 West Pharmaceutical 集体诉讼的首席原告。该案标题为 New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.)，指控西方制药及其部分现任和前任高管违反 1934 年证券交易法。
</div>If you suffered substantial losses and wish to serve as lead plaintiff of the West Pharmaceutical class action lawsuit, please provide your information here:
<div class="lb-trans">如果您遭受了重大损失并希望担任 West Pharmaceutical 集体诉讼的首席原告，请在此提供您的信息：
</div>https://www.rgrdlaw.com/cases-west-pharmaceutical-services-inc-class-action-lawsuit-wst.html
<div class="lb-trans">https://www.rgrdlaw.com/cases-west-pharmaceutical-services-inc-class-action-lawsuit-wst.html
</div>You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].
<div class="lb-trans">您也可以通过拨打 800/449-4900 或发送电子邮件至 [email protected] 联系 Robbins Geller 的律师 J.C. Sanchez 或 Jennifer N. Caringal。
</div>CASE ALLEGATIONS: West Pharmaceutical designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products.
<div class="lb-trans">案件指控：西方制药设计、制造和销售用于注射药物和医疗产品的封闭和输送系统。
</div>The West Pharmaceutical class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West Pharmaceutical was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (ii) West Pharmaceutical's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West Pharmaceutical's profit margins due to operational inefficiencies; and (iii) these margin pressures created the risk of costly restructuring activities, including West Pharmaceutical's exit from continuous glucose monitoring (&#34;CGM&#34;) contracts with long-standing customers.
<div class="lb-trans">West Pharmaceutical 集体诉讼指控被告在整个诉讼期间做出了虚假和/或误导性的陈述，和/或未能披露：(i) 尽管声称对客户需求有强烈的可见性，并将逆风归因于暂时的 COVID 相关产品去库存，西方制药实际上在其高利润的高价值产品组合中经历了显著且持续的去库存；(ii) 西方制药的 SmartDose 设备，虽然被定位为高利润增长产品，但由于运营效率低下，对西方制药的利润率造成了很大稀释；以及 (iii) 这些利润压力导致了高昂的重组活动风险，包括西方制药退出与长期客户的连续血糖监测（&#34;CGM&#34;）合同。
</div>The West Pharmaceutical class action lawsuit further alleges that on February 13, 2025, West Pharmaceutical issued its 2025 revenue forecast in the range of $2.88 billion to $2.91 billion, significantly below expectations. According to the complaint, West Pharmaceutical attributed the disappointing guidance in part to Contract Manufacturing headwinds, including the loss of two major CGM customers that had begun transitioning to in-house manufacturing of next-generation devices because West Pharmaceutical &#34;made the decision to not participate going forward as our financial thresholds cannot be achieved.&#34; The West Pharmaceutical class action lawsuit further alleges that West Pharmaceutical also revealed that its SmartDose wearable injector will become margin dilutive in 2025 due to lower pricing. On this news, the price of West Pharmaceutical's stock fell more than 38%.
<div class="lb-trans">West Pharmaceutical 集体诉讼进一步指控，2025 年 2 月 13 日，西方制药发布了 2025 年的收入预测，范围在 28.8 亿美元到 29.1 亿美元之间，远低于预期。根据投诉，西方制药将令人失望的指导部分归因于合同制造的逆风，包括失去两家主要 CGM 客户，这些客户已开始转向内部制造下一代设备，因为西方制药&#34;决定不再参与，因为我们的财务门槛无法实现。&#34; West Pharmaceutical 集体诉讼进一步指控，西方制药还透露，其 SmartDose 可穿戴注射器将在 2025 年因降价而变得利润稀释。对此消息，西方制药的股票价格下跌超过 38%。
</div>THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired West Pharmaceutical common stock during the Class Period to seek appointment as lead plaintiff in the West Pharmaceutical class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the West Pharmaceutical class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the West Pharmaceutical class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the West Pharmaceutical class action lawsuit.
<div class="lb-trans">首席原告流程：1995 年《私人证券诉讼改革法》允许在诉讼期间购买或收购西方制药普通股的任何投资者申请成为 West Pharmaceutical 集体诉讼的首席原告。首席原告通常是寻求救济的潜在集体中财务利益最大的动议者，同时也是潜在集体的典型和适当代表。首席原告代表所有其他集体成员指导 West Pharmaceutical 集体诉讼。首席原告可以选择其选择的律师事务所来进行 West Pharmaceutical 集体诉讼。投资者分享任何潜在未来赔偿的能力并不依赖于担任 West Pharmaceutical 集体诉讼的首席原告。
</div>ABOUT ROBBINS GELLER: Robbins Geller Rudman &amp; Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
<div class="lb-trans">关于 ROBBINS GELLER：Robbins Geller Rudman &amp; Dowd LLP 是全球领先的律师事务所之一，代表投资者进行证券欺诈和股东诉讼。我们的事务所过去五年中有四年在 ISS 证券集体诉讼服务排名中名列第一，为投资者争取到最多的货币救济。根据 ISS，2024 年我们为证券相关集体诉讼案件追回了超过 25 亿美元的赔偿，超过了接下来五家律师事务所的总和。Robbins Geller 在 10 个办公室拥有 200 名律师，是全球最大的原告律师事务所之一，事务所的律师获得了历史上许多最大的证券集体诉讼赔偿，包括历史上最大的赔偿——72 亿美元——在 In re Enron Corp. Sec. Litig. 案件中。有关更多信息，请访问以下页面：
</div>https://www.rgrdlaw.com/services-litigation-securities-fraud.html
<div class="lb-trans">https://www.rgrdlaw.com/services-litigation-securities-fraud.html
</div>Past results do not guarantee future outcomes.
<div class="lb-trans">过去的结果并不保证未来的结果。
</div>Services may be performed by attorneys in any of our offices.
<div class="lb-trans">服务可能由我们任何办公室的律师提供。
</div>Contact:
<div class="lb-trans">联系方式：
</div>Robbins Geller Rudman &amp; Dowd LLP
<div class="lb-trans">Robbins Geller Rudman &amp; Dowd LLP
</div>J.C. Sanchez, Jennifer N. Caringal
<div class="lb-trans">J.C. Sanchez, Jennifer N. Caringal
</div>655 W. Broadway, Suite 1900, San Diego, CA 92101
<div class="lb-trans">655 W. Broadway, Suite 1900, San Diego, CA 92101
</div>800-449-4900
<div class="lb-trans">800-449-4900
</div>[email protected]
<div class="lb-trans">[email protected]
</div>SOURCE Robbins Geller Rudman &amp; Dowd LLP
<div class="lb-trans">来源 Robbins Geller Rudman &amp; Dowd LLP
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNTEyJk5ld3NJdGVtSWQ9TEE4NDU4OCZUcmFuc21pc3Npb25fSWQ9MjAyNTA1MTIwNTA1UFJfTkVXU19VU1BSX19fX19MQTg0NTg4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA84588&amp;Transmission_Id=202505120505PR_NEWS_USPR_____LA84588&amp;DateId=20250512"/>

05:05 ET
			
			
				WST INVESTOR NOTICE: West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

西氏医药服务投资者通知：西氏医药服务公司投资者若遭受重大损失，有机会主导集体诉讼